Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - mesalazine 1 g;   - modified release tablet - 1 g - active: mesalazine 1 g   excipient: ethylcellulose magnesium stearate microcrystalline cellulose povidone purified talc - treatment of mild to moderate ulcerative colitis

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - mesalazine 250mg - modified release tablet - 250 mg - active: mesalazine 250mg excipient: acetone ethylcellulose isopropyl alcohol magnesium stearate microcrystalline cellulose povidone purified talc purified water

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - mesalazine 500mg;   - modified release tablet - 500 mg - active: mesalazine 500mg   excipient: ethylcellulose magnesium stearate microcrystalline cellulose povidone purified talc - treatment of mild to moderate ulcerative colitis.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - mesalazine 1 g;   - suppository - 1 g - active: mesalazine 1 g   excipient: macrogol 6000 magnesium stearate povidone purified talc - treatment of ulcerative proctitis.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - mesalazine 4 g;   - modified release granules - 4 g - active: mesalazine 4 g   excipient: ethylcellulose povidone - treatment of mild to moderate ulcerative colitis

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - tretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: purified water; glycerol; yellow beeswax; iron oxide yellow; gelatin; titanium dioxide; iron oxide red; soya oil; partially hydrogenated soya oil; hydrogenated soya oil; maize starch; sorbitol; mannitol - vesanoid should be used for induction of remission in acute promyelocytic leukemia (apl; fab classification aml-m3). previously untreated patients as well as patients who relapse after or are refractory to standard chemotherapy (daunorubicin and cytosine arabinoside (ara-c)or equivalent therapies) may be treated with vesanoid. following complete remission, consolidation full dose chemotherapy should be employed. a loss of responsiveness to vesanoid has been reported among patients maintained on vesanoid. the median time to relapse for patients maintained on vesanoid is 4 to 6 months.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - follitropin delta 12ug - solution for injection - active: follitropin delta 12ug excipient: dibasic sodium phosphate dodecahydrate methionine phenol phosphoric acid polysorbate 20 sodium hydroxide sodium sulfate decahydrate water for injection - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - follitropin delta 36ug - solution for injection - active: follitropin delta 36ug excipient: dibasic sodium phosphate dodecahydrate methionine phenol phosphoric acid polysorbate 20 sodium hydroxide sodium sulfate decahydrate water for injection - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - follitropin delta 72ug - solution for injection - active: follitropin delta 72ug excipient: dibasic sodium phosphate dodecahydrate methionine phenol phosphoric acid polysorbate 20 sodium hydroxide sodium sulfate decahydrate water for injection - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.1mg equivalent to 0.089 mg free base - tablet - 0.1 mg - active: desmopressin acetate trihydrate 0.1mg equivalent to 0.089 mg free base excipient: lactose monohydrate magnesium stearate potato starch povidone